All posts by Adam

Dodgy reporting, Economics, Politics

Student tuition fees and disadvantaged applicants

14 Comments

Those of you who have known me for a while will remember that I used to blog on the now defunct Dianthus Medical website. The Internet Archive has kept some of those blogposts for posterity, but sadly not all of them. As I promised when I started this blog, I will get round to putting all those posts back on the internet one of these days, but I’m afraid I haven’t got round to that just yet.

But in the meantime, I’m going to repost one of those blogposts here, as it has just become beautifully relevant again. About this time last year, UCAS (the body responsible for university admissions in the UK) published a report which claimed to show that applications to university from disadvantaged young people  were increasing proportionately more than applications from the more affluent, or in other words, the gap between rich and poor was narrowing.

Sadly, the report showed no such thing. The claim was based on a schoolboy error in statistics.

Anyway, UCAS have recently published their next annual report. Again, this claims to show that the gap between rich and poor is narrowing, but doesn’t. Again, we see the same inaccurate headlines in the media that naively take the report’s conclusions at face value, and we see exactly the same schoolboy error in the way the statistics were analysed in the report.

So as what I wrote last year is still completely relevant today, here goes…

One of the most significant political events of the current Parliament has been the huge increase in student tuition fees, which mean that most university students now need to pay £9000 per year for their education.

One of the arguments against this rise used by its opponents was that it would put off young people from disadvantaged backgrounds from applying to university. Supporters of the new system argued that it would not, as students can borrow the money via a student loan to be paid back over a period of decades, so no-one would have to find the money up front.

The new fees came into effect in 2012, so we should now have some empirical data that should allow us to find out who was right. So what do the statistics show? Have people from disadvantaged backgrounds been deterred from applying to university?

A report was published earlier this year by UCAS, the organisation responsible for handling applications to university. This specifically addresses the question of applications from disadvantaged areas. This shows (see page 17 of the report) that although there was a small drop in application rates from the most disadvantaged areas immediately after the new fees came into effect, from 18.0% in 2011 to 17.5% in 2012, the rates have since risen to 20.5% in 2014. And the ratio of the rate of applications from the most advantaged areas to the most disadvantaged areas fell from 3.0 in 2011 to 2.5 in 2014.

So, case closed, then? Clearly the new fees have not stopped people from disadvantaged areas applying to university?

Actually, no. It’s really not that simple. You see, there is a big statistical problem with the data.

That problem is known as regression to the mean. This is a tendency of characteristics with particularly high or low values to become more like average values over time. It’s something we know all about in clinical trials, and is one of the reasons why clinical trials need to include control groups if they are going to give reliable data. For example, in a trial of a medication for high blood pressure, you would expect patients’ blood pressure to decrease during the trial no matter what you do to them, as they had to have high blood pressure at the start of the trial or they wouldn’t have been included in it in the first place.

In the case of the university admission statistics, the specific problem is the precise way in which “disadvantaged areas” and “advantaged areas” were defined.

The advantage or disadvantage of an area was defined by the proportion of young people participating in higher education during the period 2000 to 2004. Since the “disadvantaged” areas were specifically defined as those areas that had previously had the lowest participation rates, it is pretty much inevitable that those rates would increase, no matter what the underlying trends were.

Similarly, the most advantaged areas were almost certain to see decreases in participation rates (at least relatively speaking, though this is somewhat complicated by the fact that overall participation rates have increased since 2004).

So the finding that the ratio of applications from most advantaged areas to those from least advantaged areas has decreased was exactly what we would expect from regression to the mean. I’m afraid this does not provide evidence that the new tuition fee regime has been beneficial to people from disadvantaged backgrounds. It is very had to disentangle any real changes in participation rates from different backgrounds from the effects of regression to the mean.

Unless anyone can point me to any better statistics on university applications from disadvantaged backgrounds, I think the question of whether the new tuition fee regime has helped or hindered social inequalities in higher education remains open.

Cancer, Dodgy reporting, Politics, Psychology

The Saatchi Bill

3 Comments

I was disappointed to see yesterday that the Saatchi Bill (or Medical Innovations Bill, to give it its official name) passed its third reading in the House of Lords.

The Saatchi Bill, if passed, will be a dreadful piece of legislation. The arguments against it have been well rehearsed elsewhere, so I won’t go into them in detail here. But briefly, the bill sets out to solve a problem that doesn’t exist, and then offers solutions that wouldn’t solve it even if it did exist.

It is based on the premise that the main reason no progress is ever made in medical research (which is nonsense to start with, of course, because progress made all the time) is because doctors are afraid to try innovative treatments in case they get sued. There is, however, absolutely no evidence that that’s true, and in any case, the bill would not help promote real innovation, as it specifically excludes the use of treatments as part of research. Without research, there is no meaningful innovation.

If the bill were simply ineffective, that would be one thing, but it’s also actively harmful. By removing the legal protection that patients  currently enjoy against doctors acting irresponsibly, the bill will be a quack’s charter. It would certainly make it more likely that someone like Stanislaw Burzynski, an out-and-out quack who makes his fortune from fleecing cancer patients by offering them ineffective and dangerous treatments, could operate legally in the UK. That would not be a good thing.

One thing that has struck me about the sorry story of the Saatchi bill is just how dishonest Maurice Saatchi and his team have been. A particularly dishonourable mention goes to the Daily Telegraph, who have been the bill’s “official media partner“. Seriously? Since when did bills going through parliament have an official media partner? Some of the articles they have written have been breathtakingly dishonest. They wrote recently that the bill had “won over its critics“,  which is very far from the truth. Pretty much the entire medical profession is against it: this response from the Academy of Royal Medical Colleges is typical. The same article says that one way the bill had won over its critics was by amending it to require that doctors treating patients under this law must publish their research. There are 2 problems with that: first, the law doesn’t apply to research, and second, it doesn’t say anything about a requirement to publish results.

In an article in the Telegraph today, Saatchi himself continued the dishonesty. As well as continuing to pretend that the bill is now widely supported, he also claimed that more than 18,000 patients responded to the Department of Health’s consultation on the bill. In fact, the total number of responses to the consultation was only 170.

The dishonesty behind the promotion of the Saatchi bill has been well documented by David Hills (aka “the Wandering Teacake”), and I’d encourage you to read his detailed blogpost.

The question that I want to ask about all this is why? Why is Maurice Saatchi doing all this? What does he have to gain from promoting a bill that’s going to be bad for patients but good for unscrupulous quacks?

I cannot know the answers to any of those questions, of course. Only Saatchi himself can know, and even he may not really know: we are not always fully aware of our own motivations. The rest of us can only speculate. But nonetheless, I think it’s interesting to speculate, so I hope you’ll bear with me while I do so.

The original impetus for the Saatchi bill came when Saatchi lost his wife to ovarian cancer. Losing a loved one to cancer is always difficult, and ovarian cancer is a particularly nasty disease. There can be no doubt that Saatchi was genuinely distressed by the experience, and deserves our sympathy.

No doubt it seemed like a good idea to try to do something about this. After all, as a member of the House of Lords, he has the opportunity to propose new legislation. It is completely understandable that if he thought a new law could help people who were dying of cancer, he would be highly motivated to introduce one.

All of that is very plausible and easy to understand. What has happened subsequently, however, is a little harder to understand.

It can’t have been very long after Saatchi proposed the bill that many people who know more about medicine than he does told him why it simply wouldn’t work, and would have harmful consequences. So I think what is harder to understand is why he persisted with the bill after all the problems with it had been explained to him.

It has been suggested that this is about personal financial gain: his advertising company works for various pharmaceutical companies, and pharmaceutical companies will gain from the bill.

However, I don’t believe that that is a plausible explanation for Saatchi’s behaviour.

For a start, I’m pretty sure that the emotional impact of losing a beloved wife is a far stronger motivator than money, particularly for someone who is already extremely rich. It’s not as if Saatchi needs more money. He’s already rich enough to buy the support of a major national newspaper and to get a truly dreadful bill through parliament.

And for another thing, I’m not at all sure that pharmaceutical companies would do particularly well out of the bill anyway. They are mostly interested in getting their drugs licensed so that they can sell them in large quantities. Selling them as a one-off to individual patients is unlikely to be at the top of their list of priorities.

For what it’s worth, my guess is that Saatchi just has difficulty admitting that he was wrong. It’s not a particularly rare personality trait. He originally thought the bill would genuinely help cancer patients, and when told otherwise, he simply ignored that information. You might see this as an example of the Dunning Kruger effect, and it’s certainly consistent with the widely accepted phenomenon of confirmation bias.

Granted, what we’re seeing here is a pretty extreme case of confirmation bias, and has required some spectacular dishonesty on the part of Saatchi to maintain the illusion that he was right all along. But Saatchi is a politician who originally made his money in advertising, and it would be hard to think of 2 more dishonest professions than politics and advertising. It perhaps shouldn’t be too surprising that dishonesty is something that comes naturally to him.

Whatever the reasons for Saatchi’s insistence on promoting the bill in the face of widespread opposition, this whole story has been a rather scary tale of how money and power can buy your way through the legislative process.

The bill still has to pass its third reading in the House of Commons before it becomes law. We can only hope that our elected MPs are smart enough to see what a travesty the bill is. If you want to write to your MP to ask them to vote against the bill, now would be a good time to do it.

Economics, Public health

Plain packaging for tobacco

Leave a comment

Plain packaging for tobacco is in the news today. The idea behind it is that requiring tobacco manufacturers to sell cigarettes in unbranded packages, where all the branding has been replaced by prominent health warnings, will reduce the number of people who smoke, and thereby benefit public health.

But will it work?

That’s an interesting question. There’s a lot of research that’s been done, though it’s fair to say none of it is conclusive. For example, there has been research on how it affects young people’s perceptions of cigarettes and on what happened to the number of people looking for help with quitting smoking after plain packaging was introduced in Australia.

But for me, those are not the most interesting pieces of evidence.

What tells me that plain packaging is overwhelmingly likely to be an extremely effective public health measure is that the tobacco industry are strongly opposed to it. They probably know far more about the likely effects than the rest of us: after all, for me, it’s just a matter of idle curiosity, but for them, millions of pounds of their income depends on it. So the fact they are against it tells us plenty.

Let’s look in a little more detail at exactly what it tells us. Advertising and branding generally has 2 related but distinguishable aims for a company that sells something. One aim is to increase their share of the market, in other words to sell more of their stuff than their competitors in the same market. The other is to increase the overall size of the market, so that they sell more, and their competitors sell more as well. Both those things can be perfectly good reasons for a company to spend their money on advertising and branding.

But the difference between those 2 aims is crucial here.

If the point of cigarette branding were just to increase market share without affecting the overall size of the market, then the tobacco industry should be thoroughly in favour of a ban. Advertising and branding budgets, when the overall size of the market is constant, are a classic prisoner’s dilemma. If all tobacco companies spend money on branding, they will all have pretty much the same share as if no-one did, so they will gain nothing, but they will spend money on branding, so they’re worse off than if they didn’t. However, they can’t afford not to spend money on branding, as then they would lose market share to their competitors, who are still spending money on it.

The ideal situation for the tobacco industry in that case would be that no-one would spend any money on branding. But how can you achieve that? For all the companies to agree not to spend money on branding might be an illegal cartel, and there’s always a risk that someone would break the agreement to increase their market share.

A government-mandated ban solves that problem nicely. If all your competitors are forced not to spend money on branding, then you don’t have to either. All the tobacco companies win.

So if that were really the situation, then you would expect the tobacco companies to be thoroughly in favour of it. But they’re not. So that tells me that we are not in the situation where the total market size is constant.

The tobacco companies must believe, and I’m going to assume here that they know what they’re doing, that cigarette branding affects the overall size of the market. If branding could increase the overall size of the market (or more realistically when smoking rates in the UK are on a long-term decline, stop it shrinking quite as fast), then it would be entirely rational for the tobacco companies to oppose mandatory plain packaging.

I don’t know about you, but that’s all the evidence I need to convince me that plain packaging is overwhelmingly likely to be an effective public health measure.

Homeopathy, Psychology

Volunteers wanted for research into homeopathy

3 Comments

I am planning a research project to explore the experiences of people who have used homeopathy, and if you have used homeopathy yourself then I would be really grateful if you would consider taking part in my research.

I would like to interview people who have used homeopathy, have been pleased with the results, but have encountered negative reactions to your use of homeopathy from others. Perhaps your GP has advised you not to use homeopathy, perhaps friends or family have told you that you were wasting your time, or perhaps you got into an argument with someone on the internet. It doesn’t matter who reacted negatively to your use of homeopathy: I am interested in learning about how users of homeopathy experience negative reactions in general.

The research will take the form of a short interview of about 30 minutes (which can take place in a location of your choice), in which I will ask you about your experiences and how they seemed to you. I shall be using a phenomenological approach to the research, which means that I am interested in learning about your experiences from your own point of view, rather than trying to fit them into a pre-existing theory.

This research is part of a degree in social sciences that I am doing with the Open University. Specifically, it is part of a module in social psychology.

In the interests of transparency, I should tell you that I am sceptical of the benefits of homeopathy. However, my intention in this research is not to challenge your views about homeopathy, it is to come to a better understanding of them.

If you decide you want to take part but later change your mind, that is fine. In that case, any materials from your interview would be returned to you or destroyed, as you prefer, and your interview would not be used in my research.

Please be assured that your participation in the study would be kept strictly confidential.

If you are interested in taking part in my research or if you would just like to know more about about the project, please feel free to contact me.

Thank you for taking the time to read this.

Adam Jacobs

Update 29 January 2015:

Many thanks to everyone who volunteered for this project. I now have enough data, and so I no longer need any more volunteers.

Cancer, Dodgy reporting, Epidemiology

Are two thirds of cancers really due to bad luck?

76 Comments

A paper published in Science has been widely reported in the media today. According to media reports, such as this one, the paper showed that two thirds of cancers are simply due to bad luck, and only one third are due to environmental, lifestyle, or genetic risk factors.

The paper shows no such thing, of course.

It’s actually quite an interesting paper, and I’d encourage you to read it in full (though sadly it’s paywalled, so you may or may not be able to). But it did not show that two thirds of cancers are due to bad luck.

What the authors did was they looked at the published literature on 31 different types of cancer (eg lung cancer, thyroid cancer, colorectal cancer, etc) and estimated 2 quantities for each type of cancer. They estimated the lifetime risk of getting the cancer, and how often stem cells divide in those tissues.

They found a very strong correlation between those two quantities: tissues in which stem cells divided frequently (eg the colon) were more likely to develop cancer than tissues in which stem cell division was less frequent (eg the brain).

The correlation was so strong, in fact, that it explained two thirds of the variation among different tissue types in their cancer incidence. The authors argue that because mutations that can lead to cancer can occur during stem cell division purely by chance, that means that two thirds of the variation in cancer risk is due to bad luck.

So, that explains where the “two thirds” figure comes from.

The problem is that it applies only to explaining the variation in cancer risk from one tissue to another. It tells us nothing about how much of the risk within a given tissue is due to modifiable factors. You could potentially see exactly the same results whether each specific type of cancer struck completely at random or whether each specific type were hugely influenced by environmental risk factors.

Let’s take lung cancer as an example. Smoking is a massively important risk factor. Here’s a study that estimated that over half of all lung cancer deaths in Japanese males were due to smoking. Or to take cervical cancer as another example, about 70% of cervical cancers are due to just 2 strains of the HPV virus.

Those are important statistics when considering what proportion of cancers are just bad luck and what proportion are due to modifiable risk factors, but they did not figure anywhere in the latest analysis.

So in fact, interesting though this paper is, it tells us absolutely nothing about what proportion of cancer cases are due to modifiable risk factors.

We often see medical research badly reported in the newspapers. Often it doesn’t matter very much. But here, I think real harm could be done. The message that comes across from the media is that cancer is just a matter of luck, so changing your lifestyle won’t make much difference anyway.

We know that lifestyle is hugely important not only for cancer, but for many other diseases as well. For the media to claim give the impression that lifestyle isn’t important, based on a misunderstanding of what the research shows, is highly irresponsible.

Edit 5 Jan 2015:

Small correction made to the last paragraph following discussion in the comments below. Old text in strikethrough, new text in bold.

Dodgy advertising, Pseudoscience

Detox: it’s all a con

116 Comments

At this time of year you will no doubt see many adverts for “detox” products. It’s a nice idea. Most of us have probably eaten and drunk rather more than we should have done over the last week or so. Wouldn’t it be nice if we could buy some nice helpful thing that would “flush all the toxins out of our system”?

This one is pretty typical. It claims to “cleanse the body from inside out”. There’s just one problem with this claim, and indeed with the claims of any other detox product you care to mention: it’s total bollocks.

Let me explain with this handy diagram:

Detox

 

There may well be things in our system that would be better off not in our system. Alcohol immediately springs to mind. But here’s the thing: millions of years of evolution have given us a liver and a pair of kidneys which, between them, do a remarkably good job of ridding the body of anything that shouldn’t be in it.

There is no scientific evidence whatsoever that any “detox” product will provide even the slightest improvement on your liver and kidneys.

If someone tries to sell you a detox product, perhaps you could ask which specific toxins it helps to remove. I have never seen that specified, but surely that is the first step to being able to show whether it works or not.

And then, in the unlikely event that this snake-oil detox salesman does tell you which toxin(s) the product is supposed to remove, ask for the evidence that it does. I guarantee you that you will not get a sensible answer.

So if your new year’s resolution is to “detox” yourself, then that’s great. Eat a healthy balanced diet, don’t drink too much alcohol, take plenty of exercise, and don’t smoke. But any money you spend on “detox” products will be 100% wasted.

Happy new year.

Dodgy reporting, Publications

Does peer review fail to spot outstanding research?

Leave a comment

A paper by Siler et al was published last week which attracted quite a bit of attention among those of us who take an interest in scientific publishing and the peer review process. It looked at the citation count of papers that had been submitted to 3 high-impact medical journals and subsequently published, either in one of those 3 journals or in another journal if rejected by one of the 3.

The accompanying press release from the publisher told us that “scientific peer review may have difficulties identifying unconventional and/or outstanding work”. This wasn’t too far off what was claimed in the paper, where Siler et al concluded that their work suggested that peer review “had difficulties in identifying outstanding or breakthrough work”.

The press release was reported uncritically by several organisations that should have known better, including Science, Nature,  and Retraction Watch.

It’s an interesting theory. The theory goes that peer reviewers don’t like to get out of their comfort zone, and while they may give good reviews to small incremental advances in their field, they don’t like radical new research that breaks new ground, so such research may be rejected.

The only problem with this theory is that Siler et al’s paper provides absolutely no data to support it.

Let’s look at what they did. They looked at 1008 manuscripts that were submitted to 3 top-tier medical journals (Annals of Internal Medicine, British Medical Journal, and The Lancet). Most of those papers were rejected, but subsequently published in other journals. Siler et al tracked the papers to see how many times each paper was cited.

Now, there we have our first problem. Using the number of times a paper is cited as a measure of groundbreaking research is pretty crude. Papers can be highly cited for many reasons, and presenting groundbreaking research is only one of them. I am writing this blogpost on the same day that I found that the 6th most important paper of the year according to “Altmetrics” (think of it as citation counting for the Facebook generation), was about how long it takes for boxes of chocolates on hospital wards to be eaten. A nicely conducted and amusing piece of research, to be sure, but hardly breaking new frontiers in science.

There’s also something rather fishy about the numbers of citations reported in the paper. The group of papers with the lowest citation rate reported in the paper were cited an average of 69.8 times each. That’s an extraordinarily high number. Of the 3 top-tier journals studied, The Lancet has the highest impact factor, at 39.2. That means that papers in The Lancet are cited an average of 39.2 times each. Doesn’t it seem rather odd that papers rejected from it are cited almost twice as often? I’m not sure what to make of that, but it does make me wonder if there is a problem with data quality.

Anyway, the main piece of evidence used to support the idea that peer review was bad at recognising outstanding research is that the 14 most highly cited papers of the 1008 papers examined were rejected by the 3 top journals. The first problem with that is that 12 of those 14 were rejected by the journals’ in-house editorial staff without being sent for peer review. So even if there were no further problems with the paper, we couldn’t draw any conclusions about failings of peer review: the failings would be down to journals’ in-house staff.

Another problem is that those 14 papers were not, of course, rejected by the peer review system. They were all published in peer reviewed journals: just not the first journal that the authors tried. So we really can’t conclude that peer review is preventing groundbreaking work from being published.

But in any case, if we ignore those flaws and ask ourselves is it still not true that groundbreaking (or at least highly cited) research is being rejected, I think we’d want to know that the highly cited research is more likely to be rejected than other research.

And I’m afraid the evidence for that is totally lacking.

Rejecting the top 14 papers sounds bad. But it’s important to realise that the overall rejection rate was very high: only 6.2% of the papers submitted were accepted. If the probability of accepting each of the top 14 papers was 6.2%, like all the others, then there is about a 40% chance that all 14 of them would be rejected. And that is ignoring the fact that looking specifically at the top 14 papers is a post-hoc analysis. The only robust way to see if the more highly cited papers were more likely to be rejected would have been to specify a specific hypothesis in advance, rather than to focus on what came out of the data as being the most impressive statistic.

So, to recap, this paper used a crude measure of whether papers were groundbreaking, did not look at what peer reviewers thought of them, found precisely zero high impact articles that were rejected by the peer review system, and found no evidence whatsoever that high-impact articles were more likely to be rejected than any others.

Call me a cynic if you like, but I’m not convinced. The peer review process is not perfect, of course, But if you want to convince me that one of its flaws is that it is biased against groundbreaking research, you’re going to have to come up with better evidence than Siler et al’s paper.

 

Dodgy advertising

Clinically proven

68 Comments

My eye was caught the other day by this advert:

Boots

Quite a bold claim, I thought. “Defends against cold and flu” would indeed be impressive, if it were true. Though I also noticed the somewhat meaningless verb “defend”. What does that mean exactly? Does it stop you getting a cold or flu in the first place? Or does it just help you recover faster if you get a cold or flu?

I had a look at the relevant page on the Boots website to see if I could find out more. It told me

“Boots Pharmaceuticals Cold & Flu Defence Nasal Spray is an easy to use nasal spray with antiviral properties containing clinically proven Carragelose to defend against colds and flu, as well as help shorten the duration and severity of both colds and flu.”

It then went on to say

“Use three times a day to help prevent a cold or flu, or several times a day at the first signs helping reduce the severity and duration of both colds and flu.”

OK, so Boots obviously want us to think that it can do both: prevent colds and flu and help treat them.

So what is the evidence? Neither the advert nor the web page had any links to any of the evidence backing up the claim that these properties were “clinically proven”. So I tweeted to Boots to ask them.

To their credit, Boots did reply to me (oddly by direct message, in case you’re wondering why I’m not linking to their tweets) with 4 papers in peer reviewed journals.

So how does the evidence stack up?

Well, the first thing to note is that although there were 4 papers, there were only 3 clinical trials: one of the papers is a combined analysis of 2 of the others. The next thing to note is that all 3 trials were of patients in the early stages of a common cold. So right away we can see that we have no evidence whatsoever that the product can help prevent a cold or flu, and no evidence whatsoever that it can treat flu.

The “clinically proven” claim is starting to look at little shaky.

But can it at least treat a common cold? That would be pretty impressive if it could. The common cold has proved remarkably resilient to anything medical science can throw at it. A treatment that actually worked against the common cold would indeed be good news.

The first of the trials was published in 2010. It was an exploratory study in 35 patients who were in the first 48 hours of a cold, but otherwise healthy. It was randomised and double-blind, and as far as I can tell from the paper, seems to have been reasonably carefully conducted. The study showed a significant benefit of the nasal spray on the primary outcome measure, namely the average of a total symptom score on days 2 to 4 after the start of dosing.

Well, I say significant. It met the conventional level of statistical significance, but only just, at P = 0.046 (that means that there’s about a 1 in 20 chance you could have seen results like this if the product were in fact completely ineffective: not a particularly high bar). The size of the effect also wasn’t very impressive: the symptom score was 4.6 out of a possible 24 in the active treatment group and 6.3 in the placebo group. Not only that, but it seems symptom scores were higher in the placebo group at baseline as well, and no attempt was made to adjust for that.

So not wholly convincing, really. On the other hand, the study did show quite an impressive effect on the secondary outcome of viral load, with a 6-fold increase from baseline to day 3 or 4 in the placebo group, but a 92% decrease in the active group. This was statistically significant at P = 0.009.

So we have some preliminary evidence of efficacy, but with such a small study and such unconvincing results on the primary outcome of symptoms, I think we’re going to have to do a lot better.

The next study was published in 2012, and included children (ages 1 to 18 years) in the early stages of a common cold. It was also randomised and double blind. The study randomised 213 patients, but only reported efficacy data for 153 of them, so that’s not a good start. It also completely failed to show any difference between the active and placebo treatments on the primary outcome measure, the symptom score from days 2 to 7. Again, there was a significant effect on viral load, but given the lack of an effect on the symptom score, it’s probably fair to say the product doesn’t work very well, if at all, in children.

The final study was published in 2013. It was again randomised and double blind, and like the first study included otherwise healthy adults in the first 48 h of a common cold. The primary endpoint was different this time, and was the duration of disease. This was a larger study than the first one, and included 211 patients.

The results were far from impressive. One of the big problems with this study was that they restricted their efficacy analysis to the subset of 118 patients with laboratory confirmed viral infection. Losing half your patients from the analysis like this is a huge problem. If you have a cold and are tempted to buy this product, you won’t know whether you have laboratory confirmed viral infection, so the results of this study may not apply to you.

But even then, the results were distinctly underwhelming. The active and placebo treatments were only significantly different in the virus-positive per-protocol population, a set of just 103 patients: less than half the total number recruited. And even then, the results were only just statistically significant, at P = 0.037. The duration of disease was reduced from 13.7 days in the placebo group to 11.6 days in the active group.

So, do I think that Boots Cold and Flu Defence is “clinically proven”? Absolutely not. There is no evidence whatsoever that it prevents a cold. There is no evidence whatsoever that it either prevents or treats flu.

There is some evidence that it may help treat a cold. It’s really hard to know whether it does or not from the studies that have been done so far. Larger studies will be needed to confirm or refute the claims. If it does help to treat a cold, it probably doesn’t help very much.

The moral of this story is that if you see the words “clinically proven” in an advert, please be aware that that phrase is completely meaningless.

Uncategorised

I’m back!

Leave a comment

Well, 2014 has been an “interesting” year for me. The company that I’d run for 15 years, Dianthus Medical, went bust in July, and I rather suddenly and unexpectedly found myself unemployed. That was not a fun experience.

Happily, I didn’t stay unemployed for long, and in the autumn I started a new job. I must confess to having been a bit nervous about this after having been my own boss since the days when we all used to think Tony Blair was one of the good guys. But I needn’t have worried: my new job has turned out to be a real joy.

Running a business was pretty damn hard work. The silver lining of the cloud that was my business going tits up is that I no longer have to worry about all that business stuff: dealing with endless government-mandated red tape, chasing customers who don’t pay on time, trying to find new business, and all that sort of thing. Now I can just get on with doing all the interesting statistical consultancy that I enjoy.

You may remember that I used to write a blog on the Dianthus Medical website. That site is sadly now defunct, but I do have a backup of all the blogposts and I will get round to putting them back on the internet one of these days.

But anyway, after a little break from blogging while I sorted my life out, I’m back. I hope you’ll come back and visit my new blog and see what interesting things from the world of statistics, medicine, and science move me to write something.